HI SB 969
died on adjournmentRELATING TO INSURANCE.
Hawaii · 2026 Regular Session · upper
Quick answers
Did HI SB 969 pass?
No. HI SB 969 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2025-12-08): Carried over to 2026 Regular Session.
What is HI SB 969 about?
Beginning 1/1/2026, requires health insurers, mutual benefit societies, health maintenance organizations, and health plans under the State's Medicaid managed care program to provide coverage for biomarker testing.
Who sponsors HI SB 969?
ELEFANTE, CHANG, RHOADS are the primary sponsors of HI SB 969.
Description
Beginning 1/1/2026, requires health insurers, mutual benefit societies, health maintenance organizations, and health plans under the State's Medicaid managed care program to provide coverage for biomarker testing.
- Introduced
- 2025-01-17
- Latest action
- 2025-12-08 — Carried over to 2026 Regular Session.
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- ELEFANTEprimary
- CHANGprimary
- RHOADSprimary
Committees
Not provided by source.
Action timeline
2025-12-08
Carried over to 2026 Regular Session.
carried-over
2025-01-23
Referred to HHS, CPN/WAM.
referral-committee
2025-01-21
Passed First Reading.
reading-1
2025-01-17
Introduced.
introduction
Versions
- SB969Compare
Documents
Votes
Not provided by source.
Related bills
- Companion bill: HB 553
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:20:09.051962Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=HI&identifier=SB 969. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.